Misplaced Pages

This is an old revision of this page, as edited by CheMoBot (talk | contribs) at 22:59, 13 November 2011 (Updating {{drugbox}} (changes to verified fields - updated 'ChemSpiderID_Ref', 'ChEMBL_Ref', 'ChEBI_Ref', 'KEGG_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref') per Chem/Drugbox validation (report [[Misplaced Pages talk:WikiProject_Pharmacology...). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Solanezumab (proposed INN) is a monoclonal antibody being investigated as a neuroprotector for patients with Alzheimer's disease.

References

1. International Nonproprietary Names for Pharmaceutical Substances (INN, prepublication copy), World Health Organization.
2. Clinical trial number NCT00749216 for "Solanezumab Safety Study in Japanese Patients With Alzheimer's Disease" at ClinicalTrials.gov
3. Clinical trial number NCT00905372 for "Effect of LY2062430 on the Progression of Alzheimer's Disease (EXPEDITION)" at ClinicalTrials.gov

This monoclonal antibody–related article is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

This drug article relating to the nervous system is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

• Drugs not assigned an ATC code
• Monoclonal antibodies
• Monoclonal antibody stubs
• Nervous system drug stubs